Meeting Banner
Abstract #0680

Using Radiogenomics to Characterize MRI-Guided Prostate Cancer Biopsy Heterogeneity

Radka Stoyanova 1 , Alan Pollack 1 , Nicholas Erho 2 , Charles Lynne 3 , Lucia Lam 2 , Christine Buerki 2 , Sakhi Abraham 1 , Merce Jorda 4 , Olexandr Kryvenko 4 , Matthew Abramowitz 1 , Elai Davicioni 2 , and Adrian Ishkanian 1

1 Radiation Oncology, University of Miami, Miami, Florida, United States, 2 GenomeDx Biosciences, Vancouver, British Columbia, Canada, 3 Urology, University of Miami, Miami, Florida, United States, 4 Pathology, University of Miami, Miami, Florida, United States

Current clinicopathological factors explain just a fraction of the observed heterogeneity in prostate cancer patient outcome. In this study we address the question whether quantitative imaging data from multiparametric (MP)-MRI are associated with gene expression characteristics (radiogenomics) and how these in turn relate to Gleason score (GS) and intra-patient versus inter-patient genomic heterogeneity. Quantitative MP-MRI-targeted diagnostic biopsies can potentially improve risk classification by directing pathological and genomic analysis to highest risk index lesions. This is the first demonstration of a link between quantitative imaging features (radiomics) with genomic features in MRI-directed prostate biopsies.

This abstract and the presentation materials are available to members only; a login is required.

Join Here